Aclaris Therapeutics, Inc. (ACRS) Financial Ratios
13 years of historical data (2013–2025) · Healthcare · Medical - Diagnostics & Research
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
5.78
↑+97% vs avg
5yr avg: 2.93
30Y Low0.5·High7.3
ROE
↑
-50.2%
↓+18% vs avg
5yr avg: -61.2%
30Y Low-113%·High-35%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
ACRS Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Aclaris Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $586M | $369M | $192M | $73M | $1.0B | $825M | $275M | $78M | $243M | $693M | $581M |
| Enterprise Value | $566M | $349M | $167M | $34M | $983M | $798M | $264M | $45M | $217M | $484M | $551M |
| P/E Ratio → | -9.17 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 74.83 | 47.18 | 10.24 | 2.35 | 34.52 | 122.00 | 42.46 | 18.48 | 24.10 | 411.77 | — |
| P/B Ratio | 5.78 | 3.58 | 1.23 | 0.47 | 5.20 | 4.18 | 7.31 | 1.12 | 1.13 | 3.08 | 3.43 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
ACRS EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 44.63 | 8.93 | 1.08 | 33.02 | 118.06 | 40.79 | 10.54 | 21.47 | 287.76 | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
ACRS Profitability
Margins and return-on-capital ratios measuring operating efficiency
Aclaris Therapeutics, Inc. earns an operating margin of -975.9%. Operating margins have compressed from -311.6% to -975.9% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -50.2% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 73.3% | 73.3% | 85.1% | 42.1% | 59.8% | 30.3% | 20.8% | 4.1% | 32.1% | 28.3% | — |
| Operating Margin | -975.9% | -975.9% | -758.2% | -311.6% | -302.0% | -1327.1% | -785.4% | -2627.3% | -1341.9% | -4303.2% | — |
| Net Profit Margin | -829.6% | -829.6% | -705.5% | -283.1% | -292.1% | -1344.0% | -787.0% | -3817.2% | -1315.4% | -4071.5% | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -50.2% | -50.2% | -84.5% | -49.9% | -44.0% | -77.3% | -94.9% | -113.2% | -60.3% | -34.7% | -36.7% |
| ROA | -34.1% | -34.1% | -63.2% | -39.2% | -34.4% | -56.4% | -60.3% | -86.3% | -51.1% | -32.7% | -35.6% |
| ROIC | -53.5% | -53.5% | -85.6% | -53.9% | -41.6% | -68.1% | -120.8% | -74.0% | -99.0% | -69.7% | -32.8% |
| ROCE | -47.7% | -47.7% | -79.9% | -48.8% | -39.0% | -63.1% | -77.3% | -68.5% | -56.5% | -36.2% | -37.0% |
ACRS Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $20M exceeds total debt of $0, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | 0.00 | 0.00 | 0.00 | 0.30 | 0.01 | 0.14 | 0.00 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.19 | -0.16 | -0.25 | -0.23 | -0.14 | -0.29 | -0.48 | -0.12 | -0.93 | -0.18 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — |
Net cash position: cash ($20M) exceeds total debt ($0)
ACRS Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Aclaris Therapeutics, Inc.'s current ratio of 5.28x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 4.16x to 5.28x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.28 | 5.28 | 3.99 | 4.16 | 10.55 | 8.94 | 3.87 | 3.74 | 6.56 | 16.37 | 27.98 |
| Quick Ratio | 5.28 | 5.28 | 3.99 | 4.16 | 10.55 | 8.94 | 3.87 | 3.74 | 6.54 | 16.86 | 27.98 |
| Cash Ratio | 5.98 | 5.98 | 3.60 | 3.85 | 9.92 | 8.35 | 3.64 | 3.27 | 6.14 | 16.37 | 22.05 |
| Asset Turnover | — | 0.05 | 0.08 | 0.16 | 0.12 | 0.03 | 0.09 | 0.04 | 0.04 | 0.01 | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | 8.66 | — | — |
| Days Sales Outstanding | — | — | 6.20 | 3.48 | 5.94 | 33.63 | 43.47 | 60.79 | 20.36 | 104.32 | — |
ACRS Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Aclaris Therapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $123M | $77M | $70M | $65M | $57M | $43M | $41M | $33M | $28M | $21M |
Peer Comparison
Compare ACRS with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 ACRSYou | $586M | -9.2 | — | — | 73.3% | -975.9% | -50.2% | -53.5% | — |
 NKTR | $2B | -8.6 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 PTGX | $6B | -48.2 | — | 113.4 | 97.3% | -343.6% | -20.2% | -21.8% | — |
 DAWN | $2B | -20.7 | — | — | 89.1% | -80.8% | -22.7% | -30.5% | — |
 RCUS | $2B | -7.5 | — | — | 96.0% | -156.3% | -63.3% | -64.1% | — |
 DERM | $102M | -6.9 | — | — | 62.8% | -24.4% | -72.6% | -56.8% | — |
 PRGO | $2B | -1.1 | 7.4 | 11.1 | 35.1% | 8.1% | -39.3% | 3.7% | 5.8 |
 INVA | $2B | 6.9 | 8.1 | 9.9 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
 SLDB | $551M | -3.6 | — | — | — | — | -109.9% | -120.8% | — |
 ABBV | $358B | 85.5 | 15.0 | 20.1 | 70.2% | 32.8% | 6214.7% | 23.9% | 2.4 |
 LLY | $921B | 42.5 | 30.6 | 102.7 | 83.8% | 45.6% | 101.2% | 41.8% | 1.4 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 13 years · Updated daily
See ACRS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ACRS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ACRS vs NKTR
Side-by-side business, growth, and profitability comparison vs Nektar Therapeutics.
Start ComparisonACRS — Frequently Asked Questions
Quick answers to the most common questions about buying ACRS stock.
What is Aclaris Therapeutics, Inc.'s P/E ratio?
Aclaris Therapeutics, Inc.'s current P/E ratio is -9.2x. This places it at the 50th percentile of its historical range.
What is Aclaris Therapeutics, Inc.'s ROE?
Aclaris Therapeutics, Inc.'s return on equity (ROE) is -50.2%. The historical average is -63.9%.
Is ACRS stock overvalued?
Based on historical data, Aclaris Therapeutics, Inc. is trading at a P/E of -9.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Aclaris Therapeutics, Inc.'s profit margins?
Aclaris Therapeutics, Inc. has 73.3% gross margin and -975.9% operating margin.